Routine scans after lung cancer treatment are a lifesaver — but not everyone is getting them

A major study published in The Journal of Thoracic and Cardiovascular Surgery confirms that staying on top of post-treatment imaging for non-small cell lung cancer (NSCLC) meaningfully improves survival. Researchers analyzed data from over 5,600 veterans with stage I–III NSCLC and found that active imaging surveillance — defined as receiving a chest CT within the prior 8 months — was significantly associated with reduced mortality risk.

The benefit was dose-dependent: patients who spent at least 50% of their follow-up time in active surveillance had a 32% lower risk of death. And when recurrences were caught through routine scans rather than symptoms, patients lived a median of 33.9 months vs. 27.1 months — nearly 7 months longer. Yet a companion analysis found that only 68% of patients received guideline-concordant chest CT, with medical oncologists outperforming surgeons, radiation oncologists, and primary care providers.

By the Numbers

• 5,650 patients analyzed; median follow-up of ~4.7 years
• Active surveillance adherence ranged from 45%–57% across years 1–5 post-treatment
• Every 6 months of active surveillance = 8% lower mortality risk (HR 0.92)
• ≥50% time in active surveillance = 32% lower risk of death
• Surveillance-detected recurrence: median OS 33.9 months vs. 27.1 months (symptom-detected)
• Only 68.4% of patients received guideline-concordant chest CT post-treatment

Why it matters: As cancer survivorship grows, gaps in post-treatment surveillance represent a fixable — and potentially life-saving — problem. These findings make a strong case for standardizing imaging follow-up protocols across all specialties involved in lung cancer care.